ESR1 and breast cancer: H3B-5942 was tested and well-tolerated in experimental mice in vivo, against different BC tumor models including ERα-wild type and ERα-mutated, demonstrating strong antiproliferative activity and it showed superiority to fulvestrant in ER+ BC models.